Modified clostridial neurotoxins with altered biological persistence

Details for Australian Patent Application No. 2002219850 (hide)

Owner Allergan Inc.

Inventors Spanoyannis, Athena; Lin, Wei-Jen; Steward, Lance E.; Aoki, Kei Roger

Agent Davies Collison Cave

Pub. Number AU-B-2002219850

PCT Pub. Number WO02/40506

Priority 60/249,540 17.11.00 US

Filing date 16 November 2001

Wipo publication date 27 May 2002

Acceptance publication date 10 August 2006

International Classifications

C07K 5/00 (2006.01) Peptides having up to four amino acids in a fully defined sequence

A61K 38/00 (2006.01) Medicinal preparations containing peptides

C12N 9/52 (2006.01) Enzymes, e.g. ligases (6.) - derived from bacteria

Event Publications

10 August 2006 Application Accepted

  Published as AU-B-2002219850

7 December 2006 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002219851

2002219849